Skip to main content
Top
Published in: Virchows Archiv 2/2010

Open Access 01-02-2010 | Invited Editorial

Soft tissue sarcomas: introduction to the Virchows Archiv review issue

Authors: Louis Guillou, Pancras C. W. Hogendoorn, Fred T. Bosman

Published in: Virchows Archiv | Issue 2/2010

Login to get access

Excerpt

Soft tissue sarcomas constitute a heterogeneous category of neoplasms composed mostly of uncommon tumours of different histology, different biology, and different outcome. Thirty years ago, the diagnosis of these neoplasms was mainly based on morphology coupled with some classical histochemical stains such as periodic acid-Schiff, reticulin, and trichrome stains. In the last 15 years, thanks to the substantial development of immunohistochemistry, cytogenetics and molecular genetic analysis significant improvements have been made regarding the classification and diagnosis of these tumors, with direct implications for clinical management and prognosis [1, 2]. Many new entities were recognized of which desmoplastic small round cell tumor and intimal sarcomas are examples. Other sarcoma entities gradually disappeared or lost in importance (e.g., the so-called malignant fibrous histiocytoma [3], hemangiopericytoma [4], and fibrosarcoma categories). During the same period of time, molecular ancillary techniques (including a vast array of polymerase chain reaction-based techniques, fluorescence in situ hybridization (FISH), conventional and array-based comparative genomic hybridization, expression arrays, direct genome sequencing, and DNA methylation analysis to name a few) allowed detailed analysis of these tumors and the resulting data facilitated better understanding of their biology (Fig. 1). In addition, thanks to improvements in nucleic acid preservation and isolation, many molecular techniques provided new parameters important for diagnostics and/or prognosis and were modified to be applicable on formalin-fixed, paraffin-embedded material (e.g., FISH, polymerase chain reaction-based techniques). This is all condensed in a substantial revision of the World Health Organization classification which combined histology with genetics [2]. Methodological advances thus allowed better understanding of biology, within turn novel classifications based upon new histogenetic concepts and robust diagnostic methods.
Literature
1.
go back to reference Hogendoorn PCW, Collin F, Daugaard S et al (2004) Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 40:1644–1654CrossRefPubMed Hogendoorn PCW, Collin F, Daugaard S et al (2004) Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 40:1644–1654CrossRefPubMed
2.
go back to reference Fletcher CDM, Unni KK, Mertens F (2002) WHO classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon Fletcher CDM, Unni KK, Mertens F (2002) WHO classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon
3.
go back to reference Fletcher CDM (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213–228PubMedCrossRef Fletcher CDM (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213–228PubMedCrossRef
4.
go back to reference Fletcher CDM (1994) Haemangiopericytoma—a dying breed? Reappraisal of an ‘entity’ and its variants: a hypothesis. Curr Diagn Pathol 1:19–23CrossRef Fletcher CDM (1994) Haemangiopericytoma—a dying breed? Reappraisal of an ‘entity’ and its variants: a hypothesis. Curr Diagn Pathol 1:19–23CrossRef
7.
go back to reference Beck AH, West RB, Van de Rijn M (2010) Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch. doi:10.1007/s00428-009-0774-2 PubMed Beck AH, West RB, Van de Rijn M (2010) Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch. doi:10.​1007/​s00428-009-0774-2 PubMed
8.
go back to reference Mohseny AB, Szuhai K, Romeo S et al (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294–305CrossRefPubMed Mohseny AB, Szuhai K, Romeo S et al (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294–305CrossRefPubMed
9.
go back to reference Cironi L, Provero P, Riggi N et al (2009) Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS ONE 4:e7904CrossRefPubMed Cironi L, Provero P, Riggi N et al (2009) Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS ONE 4:e7904CrossRefPubMed
10.
go back to reference Riggi N, Cironi L, Provero P et al (2005) Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65:11459–11468CrossRefPubMed Riggi N, Cironi L, Provero P et al (2005) Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65:11459–11468CrossRefPubMed
11.
go back to reference Riggi N, Cironi L, Suva ML et al (2007) Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J Pathol 213:4–20CrossRefPubMed Riggi N, Cironi L, Suva ML et al (2007) Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J Pathol 213:4–20CrossRefPubMed
12.
go back to reference Riggi N, Cironi L, Provero P et al (2006) Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 66:7016–7023CrossRefPubMed Riggi N, Cironi L, Provero P et al (2006) Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 66:7016–7023CrossRefPubMed
13.
go back to reference Riggi N, Suva ML, Suva D et al (2008) EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68:2176–2185CrossRefPubMed Riggi N, Suva ML, Suva D et al (2008) EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68:2176–2185CrossRefPubMed
14.
go back to reference Suva ML, Cironi L, Riggi N et al (2007) Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations. J Pathol 213:117–130CrossRefPubMed Suva ML, Cironi L, Riggi N et al (2007) Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations. J Pathol 213:117–130CrossRefPubMed
15.
go back to reference Suva ML, Riggi N, Stehle JC et al (2009) Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res 69:1776–1781CrossRefPubMed Suva ML, Riggi N, Stehle JC et al (2009) Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res 69:1776–1781CrossRefPubMed
16.
go back to reference Ladanyi M (1995) The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 4:162–173CrossRefPubMed Ladanyi M (1995) The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 4:162–173CrossRefPubMed
17.
go back to reference Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations in c-kit in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations in c-kit in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed
18.
23.
go back to reference Willems SM, Schrage YM, Baelde JJ et al (2008) Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology 52:465–474CrossRefPubMed Willems SM, Schrage YM, Baelde JJ et al (2008) Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology 52:465–474CrossRefPubMed
24.
go back to reference Willems SM, Mohseny AB, Balog C et al (2009) Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 7:1301 Willems SM, Mohseny AB, Balog C et al (2009) Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 7:1301
25.
go back to reference Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM (1999) Myxoid tumours of soft tissue. Histopathology 35:291–312CrossRefPubMed Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM (1999) Myxoid tumours of soft tissue. Histopathology 35:291–312CrossRefPubMed
26.
go back to reference Willems SM, Wiweger M, Frans Graadt van Roggen J et al. (2010) Running GAGs: myxoid matrix revisited. What’s in it for the pathologist? Virchows Arch. doi:10.1007/s00428-009-0822-y Willems SM, Wiweger M, Frans Graadt van Roggen J et al. (2010) Running GAGs: myxoid matrix revisited. What’s in it for the pathologist? Virchows Arch. doi:10.​1007/​s00428-009-0822-y
28.
go back to reference Verweij J, van Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011 Verweij J, van Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011
Metadata
Title
Soft tissue sarcomas: introduction to the Virchows Archiv review issue
Authors
Louis Guillou
Pancras C. W. Hogendoorn
Fred T. Bosman
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 2/2010
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-009-0875-y

Other articles of this Issue 2/2010

Virchows Archiv 2/2010 Go to the issue